Benzinga · Aug 14, 2026
Achieve Life Sciences Enters ATM Sale Agreement With Jefferies For Up To $150M In Common Stock
-SEC Filing
AC
NASDAQ · ACHV
Achieve Life Sciences, Inc.
Healthcare · Biotechnology
$7.42
Up+$0.41 (+5.53%)
Updated Sep 17, 2026, 7:00 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 242.75M
- P/E ratio
- -3.02
- Dividend yield
- 0.00%
- 52-week range
- $2.62 – $8.64
- Volume
- 1.91M
- Avg. volume
- 651.46K
Price performance
ACHV price history
1M range · 20 trading sessions · Daily adjusted prices
ACHV closed at $7.42 after 20 trading sessions, down 13.01% for the selected period.
- Last close
- $7.42
- Period change
- -13.01%
- Period low
- $7.06
- Period high
- $8.53
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $7.43 | $7.62 | $7.265 | $7.42 | 1.91M |
| Sep 15, 2026 | $7.22 | $7.33 | $7.018 | $7.32 | 1.39M |
| Sep 14, 2026 | $7.06 | $7.29 | $7.0199 | $7.23 | 1.43M |
| Sep 11, 2026 | $7.38 | $7.44 | $7.01 | $7.06 | 1.46M |
| Sep 10, 2026 | $7.48 | $7.56 | $7.21 | $7.28 | 2.48M |
| Sep 9, 2026 | $7.82 | $7.85 | $7.52 | $7.54 | 2.37M |
| Sep 8, 2026 | $8.32 | $8.3401 | $7.815 | $7.84 | 3.53M |
| Sep 4, 2026 | $8.20 | $8.56 | $8.10 | $8.49 | 886.37K |
| Sep 3, 2026 | $8.49 | $8.64 | $8.205 | $8.31 | 1.53M |
| Sep 2, 2026 | $8.27 | $8.52 | $8.25 | $8.48 | 1.04M |
| Sep 1, 2026 | $7.83 | $8.40 | $7.83 | $8.25 | 1.65M |
| Aug 31, 2026 | $8.07 | $8.14 | $7.82 | $7.94 | 1.06M |
| Aug 28, 2026 | $8.17 | $8.22 | $7.9545 | $8.10 | 988.99K |
| Aug 27, 2026 | $8.31 | $8.40 | $8.16 | $8.18 | 989.42K |
| Aug 26, 2026 | $8.20 | $8.34 | $8.02 | $8.27 | 1.32M |
| Aug 25, 2026 | $8.04 | $8.42 | $8.01 | $8.17 | 1.32M |
| Aug 24, 2026 | $7.99 | $8.12 | $7.68 | $7.94 | 920.74K |
| Aug 21, 2026 | $8.11 | $8.194 | $7.90 | $7.99 | 1.06M |
| Aug 20, 2026 | $8.42 | $8.46 | $7.96 | $8.02 | 1.45M |
| Aug 19, 2026 | $7.62 | $8.61 | $7.62 | $8.53 | 3.92M |
Latest ACHV news
The latest Smart Investors Daily articles mentioning ACHV.
Stock researchCompany · Overview
ACHV research
Overview
Company profile and research snapshot.
Company profile
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $4.75
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Morgan Stanley | Overweight | — |
| Jun 22, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2026 | Canaccord Genuity | Buy | — |
| Apr 16, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 25, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts changed outlook on top names. Check analyst ratings page for all changes. See what analysts think of MTN stock.
Benzinga · Aug 13, 2026
Morgan Stanley Initiates Coverage On Achieve Life Sciences with Overweight Rating, Announces Price Target of $13
Morgan Stanley analyst Maxwell Skor initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Overweight rating and announces Price Target of $13.
Benzinga · Aug 11, 2026
Achieve Life Sciences Q2 EPS $(0.80) Misses $(0.16) Estimate
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.16) by 400 percent. This is a 116.22 percent decrease over losses of $(0.37) per
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
